Omics Information Research Articles

Sequential lipidomic, metabolomic, and proteomic analyses of serum, liver, and heart tissue specimens from peroxisomal biogenesis factor 11\u03b1 knockout mice

Peroxisomes are versatile single membrane-enclosed cytoplasmic organelles, involved in reactive oxygen species (ROS) and lipid metabolism and diverse other metabolic processes. Peroxisomal disorders result from mutations in Pex genes-encoded proteins named peroxins (PEX proteins) and single peroxisomal enzyme deficiencies. The PEX11 protein family (α, β, and γ isoforms) plays an important role in peroxisomal proliferation and fission. However, their specific functions and the metabolic impact caused by their deficiencies have not been precisely characterized. To understand the systemic molecular alterations caused by peroxisomal defects, here we utilized untreated peroxisomal biogenesis factor 11α knockout (Pex11α KO) mouse model and performed serial relative-quantitative lipidomic, metabolomic, and proteomic analyses of serum, liver, and heart tissue homogenates. We demonstrated significant specific changes in the abundances of multiple lipid species, polar metabolites, and proteins and dysregulated metabolic pathways in distinct biological specimens of the Pex11α KO adult mice in comparison to the wild type (WT) controls. Overall, the present study reports comprehensive semi-quantitative molecular omics information of the Pex11α KO mice, which might serve in the future as a reference for a better understanding of the roles of Pex11α and underlying pathophysiological mechanisms of peroxisomal biogenesis disorders.Graphical abstract

Modeling of Tumor Growth with Input from Patient-Specific Metabolomic Data.

Advances in omic technologies have provided insight into cancer progression and treatment response. However, the nonlinear characteristics of cancer growth present a challenge to bridge from the molecular- to the tissue-scale, as tumor behavior cannot be encapsulated by the sum of the individual molecular details gleaned experimentally. Mathematical modeling and computational simulation have been traditionally employed to facilitate analysis of nonlinear systems. In this study, for the first time tumor metabolomic data are linked via mathematical modeling to the tumor tissue-scale behavior, showing the capability to mechanistically simulate cancer progression personalized to omic information obtainable from patient tumor core biopsy analysis. Generally, a higher degree of metabolic dysregulation has been correlated with more aggressive tumor behavior. Accordingly, key parameters influenced by metabolomic data in this model include tumor proliferation, vascularization, aggressiveness, lactic acid production, monocyte infiltration and macrophage polarization, and drug effect. The model enables evaluating interactions of interest between these parameters which drive tumor growth based on the metabolomic data. The results show that the model can group patients consistently with the clinically observed outcomes of response/non-response to chemotherapy. This modeling approach provides a first step towards evaluation of tumor growth based on tumor-specific metabolomic data.

A novel 14-gene signature for overall survival in lung adenocarcinoma based on the Bayesian hierarchical Cox proportional hazards model

There have been few investigations of cancer prognosis models based on Bayesian hierarchical models. In this study, we used a novel Bayesian method to screen mRNAs and estimate the effects of mRNAs on the prognosis of patients with lung adenocarcinoma. Based on the identified mRNAs, we can build a prognostic model combining mRNAs and clinical features, allowing us to explore new molecules with the potential to predict the prognosis of lung adenocarcinoma. The mRNA data (n = 594) and clinical data (n = 470) for lung adenocarcinoma were obtained from the TCGA database. Gene set enrichment analysis (GSEA), univariate Cox proportional hazards regression, and the Bayesian hierarchical Cox proportional hazards model were used to explore the mRNAs related to the prognosis of lung adenocarcinoma. Multivariate Cox proportional hazard regression was used to identify independent markers. The prediction performance of the prognostic model was evaluated not only by the internal cross-validation but also by the external validation based on the GEO dataset (n = 437). With the Bayesian hierarchical Cox proportional hazards model, a 14-gene signature that included CPS1, CTPS2, DARS2, IGFBP3, MCM5, MCM7, NME4, NT5E, PLK1, POLR3G, PTTG1, SERPINB5, TXNRD1, and TYMS was established to predict overall survival in lung adenocarcinoma. Multivariate analysis demonstrated that the 14-gene signature (HR 3.960, 95% CI 2.710–5.786), T classification (T1, reference; T3, HR 1.925, 95% CI 1.104–3.355) and N classification (N0, reference; N1, HR 2.212, 95% CI 1.520–3.220; N2, HR 2.260, 95% CI 1.499–3.409) were independent predictors. The C-index of the model was 0.733 and 0.735, respectively, after performing cross-validation and external validation, a nomogram was provided for better prediction in clinical application. Bayesian hierarchical Cox proportional hazards models can be used to integrate high-dimensional omics information into a prediction model for lung adenocarcinoma to improve the prognostic prediction and discover potential targets. This approach may be a powerful predictive tool for clinicians treating malignant tumours.

Comparison of machine-learning algorithms for the prediction of Current Procedural Terminology (CPT) codes from pathology reports

BackgroundPathology reports serve as an auditable trial of a patient’s clinical narrative, containing text pertaining to diagnosis, prognosis, and specimen processing. Recent works have utilized natural language processing (NLP) pipelines, which include rule-based or machine-learning analytics, to uncover textual patterns that inform clinical endpoints and biomarker information. Although deep learning methods have come to the forefront of NLP, there have been limited comparisons with the performance of other machine-learning methods in extracting key insights for the prediction of medical procedure information, which is used to inform reimbursement for pathology departments. In addition, the utility of combining and ranking information from multiple report subfields as compared with exclusively using the diagnostic field for the prediction of Current Procedural Terminology (CPT) codes and signing pathologists remains unclear. MethodsAfter preprocessing pathology reports, we utilized advanced topic modeling to identify topics that characterize a cohort of 93,039 pathology reports at the Dartmouth-Hitchcock Department of Pathology and Laboratory Medicine (DPLM). We separately compared XGBoost, SVM, and BERT (Bidirectional Encoder Representation from Transformers) methodologies for the prediction of primary CPT codes (CPT 88302, 88304, 88305, 88307, 88309) as well as 38 ancillary CPT codes, using both the diagnostic text alone and text from all subfields. We performed similar analyses for characterizing text from a group of the 20 pathologists with the most pathology report sign-outs. Finally, we uncovered important report subcomponents by using model explanation techniques. ResultsWe identified 20 topics that pertained to diagnostic and procedural information. Operating on diagnostic text alone, BERT outperformed XGBoost for the prediction of primary CPT codes. When utilizing all report subfields, XGBoost outperformed BERT for the prediction of primary CPT codes. Utilizing additional subfields of the pathology report increased prediction accuracy across ancillary CPT codes, and performance gains for using additional report subfields were high for the XGBoost model for primary CPT codes. Misclassifications of CPT codes were between codes of a similar complexity, and misclassifications between pathologists were subspecialty related. ConclusionsOur approach generated CPT code predictions with an accuracy that was higher than previously reported. Although diagnostic text is an important source of information, additional insights may be extracted from other report subfields. Although BERT approaches performed comparably to the XGBoost approaches, they may lend valuable information to pipelines that combine image, text, and -omics information. Future resource-saving opportunities exist to help hospitals detect mis-billing, standardize report text, and estimate productivity metrics that pertain to pathologist compensation (RVUs).

OMICS in Chronic Kidney Disease: Focus on Prognosis and Prediction.

Chronic kidney disease (CKD) patients are characterized by a high residual risk for cardiovascular (CV) events and CKD progression. This has prompted the implementation of new prognostic and predictive biomarkers with the aim of mitigating this risk. The ‘omics’ techniques, namely genomics, proteomics, metabolomics, and transcriptomics, are excellent candidates to provide a better understanding of pathophysiologic mechanisms of disease in CKD, to improve risk stratification of patients with respect to future cardiovascular events, and to identify CKD patients who are likely to respond to a treatment. Following such a strategy, a reliable risk of future events for a particular patient may be calculated and consequently the patient would also benefit from the best available treatment based on their risk profile. Moreover, a further step forward can be represented by the aggregation of multiple omics information by combining different techniques and/or different biological samples. This has already been shown to yield additional information by revealing with more accuracy the exact individual pathway of disease.

Cell population-based framework of genetic epidemiology in the single-cell omics era.

Genetic epidemiology is a rapidly advancing field due to the recent availability of large amounts of omics data. In recent years, it has become possible to obtain omics information at the single-cell level, so genetic epidemiological models need to be updated to integrate with single-cell expression data. In this perspective paper, we propose a cell population-based framework for genetic epidemiology in the single-cell era. In this framework, genetic diversity influences phenotypic diversity through the diversity of cell population profiles, which are defined as high-dimensional probability distributions of the state spaces of biomolecules of each omics layer. We discuss how biomolecular experimental measurement data can capture the different properties of this distribution. In particular, single-cell data constitute a sample from this population distribution where only some coordinate values are observable. From a data analysis standpoint, we introduce methodology for feature extraction from cell population profiles. Finally, we discuss how this framework can be applied not only to genetic epidemiology but also to systems biology.

Emergency medicine: past, present, and future challenges

Emergency medicine: past, present, and future challenges

Exploring Biological Impacts of Prenatal Nutrition and Selection for Residual Feed Intake on Beef Cattle Using Omics Technologies: A Review.

Approximately 70% of the cost of beef production is impacted by dietary intake. Maximizing production efficiency of beef cattle requires not only genetic selection to maximize feed efficiency (i.e., residual feed intake (RFI)), but also adequate nutrition throughout all stages of growth and development to maximize efficiency of growth and reproductive capacity, even during gestation. RFI as a measure of feed efficiency in cattle has been recently accepted and used in the beef industry, but the effect of selection for RFI upon the dynamics of gestation has not been extensively studied, especially in the context of fluctuating energy supply to the dam and fetus. Nutrient restriction during gestation has been shown to negatively affect postnatal growth and development as well as fertility of beef cattle offspring. This, when combined with the genetic potential for RFI, may significantly affect energy partitioning in the offspring and subsequently important performance traits. In this review, we discuss: 1) the importance of RFI as a measure of feed efficiency and how it can affect other economic traits in beef cattle; 2) the influence of prenatal nutrition on physiological phenotypes in calves; 3) the benefits of investigating the interaction of genetic selection for RFI and prenatal nutrition; 4) how metabolomics, transcriptomics, and epigenomics have been employed to investigate the underlying biology associated with prenatal nutrition, RFI, or their interactions in beef cattle; and 5) how the integration of omics information is adding a level of deeper understanding of the genetic architecture of phenotypic traits in cattle.

Integrative eQTL-weighted hierarchical Cox models for SNP-set based time-to-event association studies

BackgroundIntegrating functional annotations into SNP-set association studies has been proven a powerful analysis strategy. Statistical methods for such integration have been developed for continuous and binary phenotypes; however, the SNP-set integrative approaches for time-to-event or survival outcomes are lacking.MethodsWe here propose IEHC, an integrative eQTL (expression quantitative trait loci) hierarchical Cox regression, for SNP-set based survival association analysis by modeling effect sizes of genetic variants as a function of eQTL via a hierarchical manner. Three p-values combination tests are developed to examine the joint effects of eQTL and genetic variants after a novel decorrelated modification of statistics for the two components. An omnibus test (IEHC-ACAT) is further adapted to aggregate the strengths of all available tests.ResultsSimulations demonstrated that the IEHC joint tests were more powerful if both eQTL and genetic variants contributed to association signal, while IEHC-ACAT was robust and often outperformed other approaches across various simulation scenarios. When applying IEHC to ten TCGA cancers by incorporating eQTL from relevant tissues of GTEx, we revealed that substantial correlations existed between the two types of effect sizes of genetic variants from TCGA and GTEx, and identified 21 (9 unique) cancer-associated genes which would otherwise be missed by approaches not incorporating eQTL.ConclusionIEHC represents a flexible, robust, and powerful approach to integrate functional omics information to enhance the power of identifying association signals for the survival risk of complex human cancers.

OAB-010: Gain(1q) promotes mitochondrial oxidative phosphorylation and suppresses interferon response and tumor immunity in multiple myeloma and other human cancers

<h3>Introduction</h3> Gain of chromosome 1q is a recurrent genomic feature of many human tumors and is present in 33-48% of newly diagnosed MMs (NDMM). Analogous to deletion of 17p, + 1q can occur as a secondary genetic event in all MM subtypes, and is associated with poor prognosis. Although uncommon in precursor stages such as monoclonal gammopathy of undetermined significance (MGUS), the prevalence of +1q rises significantly in symptomatic MM, and at relapse, suggesting roles in malignant transformation and treatment escape. The molecular mechanisms underlying these associations remain poorly understood. Here, we report an analysis of the transcriptional consequences of +1q in single MM cells and in bulk tumor samples. <h3>Methods</h3> To define the molecular consequences of + 1q at a cellular level, we performed single cell RNA-sequencing (scRNA-seq) and single-cell inferred CNV (sciCNV) analysis of primary MM bone marrow samples. This provided paired DNA/RNA omics information within single cells. From MM samples containing intra-clonal populations with and without +1q we directly examined the effects of +1q on gene expression. The effects of +1q were delineated using intra-clonal isogenic sibling cells lacking +1q as controls. We validated our findings using 10 tumor cohorts, including 2 MM cohorts representing >1300 NDMM patients and 8 non-MM cohorts representing 3,915 patients with other malignancies. <h3>Results</h3> From these studies we show that primary MM cells with +1q significantly upregulate mitochondrial oxidative phosphorylation (OXPHOS), causing increased reactive oxygen species and reduced energy stress, compared with isogenic sibling cells without +1q. Despite increased OXPHOS, +1q cells do not appear to experience increased hypoxia nor reduced glycolysis, suggesting that they continue to benefit from aerobic glycolysis (Warburg metabolism). At the same time +1q MM cells overexpress ADAR and suppress IFN type 1 and 2 responses, repressing tumor immunity. Overexpression of CD46, CFH, CFHR1, CHFR5, ARPC5 and SELL from +1q further suppress pathways involved in tumor immune recognition, particularly by complement and antibodies. MM tumors overexpressing MYC are enriched amongst +1q samples, with MYC co-operating with MCL1 to promote mitochondrial oxidative phosphorylation, leading to apparent enrichment of a MYC gene expression signature in +1q samples, though MYC itself is not increased by +1q. From MM registry data, +1q cooperates with MYC to promote OXPHOS, and OXPHOS strongly predicts patient survival, particularly in high-risk t(4;14) and del(17p) subtypes. Examination of 8 non-MM tumor cohorts reveals that other human cancers with +1q similarly upregulate OXPHOS and MYC programs and/or suppress tumor immunity (IFN-g and -a responses, complement pathways and allograft rejection). <h3>Conclusion</h3> Overall, from these multi-omic analyses we identify critical reprogramming events in MM and other human cancers that arise from +1q and that predict patient survival.

Biomarkers for respiratory diseases: Present applications and future discoveries

AbstractBiomarkers such as clinical characteristics and laboratory indices have been widely used in many respiratory diseases, such as chronic airway diseases, lung infection, lung cancer and acute respiratory distress syndrome. As such, various non‐invasive and invasive samples, such as blood, urine, induced sputum, bronchoalveolar lavage fluid and lung biopsy are currently being collected. Omics‐based discovery strategies facilitate the identification of next‐generation candidate biomarkers. The identification and integration of multiple omics biomarkers (genomics, epigenomics, proteomics, metabolomics and radiomics) can answer many unsolved questions about respiratory diseases. The ultimate realization of the translation of novel biomarkers into clinical practice is a major challenge because good biomarkers must be sensitive, technically feasible, non‐invasive, non‐expensive and most importantly, validated. The four stages of clinical trial design in the development of biomarkers are also discussed. The concept of systems biology not only focuses on novel molecular biomarkers but also integrates clinical, laboratory and omics information as a whole. Finally, developing multiple biomarker panels is a goal to improve the healthcare of respiratory diseases.

Dose-response metabolomics and pathway sensitivity to map molecular cartography of bisphenol A exposure

In the toxicological regime, the toxicological endpoint and its dose-response relationship are two of the most prominent characters in conducting a risk assessment for chemical exposure. Systems biological methods have been used to comprehensively characterize the impact of toxicants on the biochemical pathways. However, the majority of the current studies are only based on single-dose, and limited information can be extrapolated to other doses from these experiments, regardless of the sensitivity of each endpoint. This study aims to understand the dose-response metabolite dysregulation pattern and metabolite sensitivity at the system-biological level. Here, we applied bisphenol A (BPA), an endocrine-disrupting chemical (EDC), as the model chemical. We first employed the global metabolomics method to characterize the metabolome of breast cancer cells (MCF-7) upon exposure to different doses (0, 20, 50, and 100 µM) of BPA. The dysregulated features with a clear dose-response relationship were also effectively picked up with an R-package named TOXcms. Overall, most metabolites were dysregulated by showing a significant dose-dependent behaviour. The results suggested that BPA exposure greatly perturbed purine metabolism and pyrimidine metabolism. Interestingly, most metabolites within the purine metabolism were described as a biphasic dose-response relationship. With the established dose-response relationship, we were able to fully map the metabolite cartography of BPA exposure within a wide range of concentrations and observe some unique patterns. Furthermore, an effective concentration of certain fold changes (e.g., EC+10 means the dose at which metabolite is 10% upregulated) and metabolite sensitivity were defined and introduced to this dose-response omics information. The result showed that the purine metabolism pathway is the most venerable target of BPA, which can be a potential endogenous biomarker for its exposure. Overall, this study applied the dose-response metabolomics method to fully understand the biochemical pathway disruption of BPA treatment at different doses. Both dose-response omics strategy and metabolite sensitivity analysis can be further considered and emphasized in future chemical risk assessments.

Trends in the Application of "Omics" to Ecotoxicology and Stress Ecology.

Our ability to predict and assess how environmental changes such as pollution and climate change affect components of the Earth’s biome is of paramount importance. This need positioned the fields of ecotoxicology and stress ecology at the center of environmental monitoring efforts. Advances in these interdisciplinary fields depend not only on conceptual leaps but also on technological advances and data integration. High-throughput “omics” technologies enabled the measurement of molecular changes at virtually all levels of an organism’s biological organization and thus continue to influence how the impacts of stressors are understood. This bibliometric review describes literature trends (2000–2020) that indicate that more different stressors than species are studied each year but that only a few stressors have been studied in more than two phyla. At the same time, the molecular responses of a diverse set of non-model species have been investigated, but cross-species comparisons are still rare. While transcriptomics studies dominated until 2016, a shift towards proteomics and multiomics studies is apparent. There is now a wealth of data at functional omics levels from many phylogenetically diverse species. This review, therefore, addresses the question of how to integrate omics information across species.

Cap analysis of gene expression (CAGE) and noncoding regulatory elements.

Cap analysis of gene expression (CAGE) was developed to detect the 5' end of RNA. Trapping of the RNA 5'-cap structure enables the enrichment and selective sequencing of complete transcripts. Upscaled high-throughput versions of CAGE have enabled the genome-wide identification of transcription start sites, including transcriptionally active promoters and enhancers. CAGE sequencing can be exploited to draw comprehensive maps of active genomic regulatory elements in a cell type- and activation-specific manner. The cells of the immune system are among the best candidates to be analyzed in humans, since they are easily accessible. In this review, we discuss how CAGE data are instrumental for integrative analyses with quantitative trait loci and omics data, and their usefulness in the mechanistic interpretation of the effects of genetic variations over the entire human genome. Integrating CAGE data with the currently available omics information will contribute to better understanding of the genome-wide association study variants that lie outside of annotated genes, deepening our knowledge on human diseases, and enabling the targeted design of more specific therapeutic interventions.

Genomic medicine on the frontier of precision medicine.

Genomic medicine has created a great deal of hope since the completion of the Human Genome Project (HGP). Genomic medicine promises disease prevention and early diagnosis in the context of precision medicine. Precision medicine as a scientific discipline has introduced as an evolution in medicine. The rapid growth of high-development technologies permits the assessment of biological systems. Study of the integrated profiles of omics, such as genome, transcriptome, proteome and other omics information lead to significant advances in personalized and precision medicine. In the context of precision medicine, pharmacogenomics can play an important role in order to discriminate responders and non-responders to medications and avoiding toxicity and achieving the optimum dose. So precision medicine in accordance with genomic medicine will transform medicine from conventional evidence-based medicine in the diagnosis and treatment towards precision based-medicine. In this review, we have summarized the related issues for genomic medicine and precision medicine.

Developing the building blocks to elucidate the impact of the urban exposome on cardiometabolic-pulmonary disease: The EU EXPANSE project.

By 2030, more than 80% of Europe's population will live in an urban environment. The urban exposome, consisting of factors such as where we live and work, where and what we eat, our social network, and what chemical and physical hazards we are exposed to, provides important targets to improve population health. The EXPANSE (EXposome Powered tools for healthy living in urbAN SEttings) project will study the impact of the urban exposome on the major contributors to Europe's burden of disease: Cardio-Metabolic and Pulmonary Disease. EXPANSE will address one of the most pertinent questions for urban planners, policy makers, and European citizens: "How to maximize one's health in a modern urban environment?" EXPANSE will take the next step in exposome research by (1) bringing together exposome and health data of more than 55 million adult Europeans and OMICS information for more than 2 million Europeans; (2) perform personalized exposome assessment for 5,000 individuals in five urban regions; (3) applying ultra-high-resolution mass-spectrometry to screen for chemicals in 10,000 blood samples; (4) evaluating the evolution of the exposome and health through the life course; and (5) evaluating the impact of changes in the urban exposome on the burden of cardiometabolic and pulmonary disease. EXPANSE will translate its insights and innovations into research and dissemination tools that will be openly accessible via the EXPANSE toolbox. By applying innovative ethics-by-design throughout the project, the social and ethical acceptability of these tools will be safeguarded. EXPANSE is part of the European Human Exposome Network.

Single-cell multi-omics sequencing: application trends, COVID-19, data analysis issues and prospects.

Single-cell sequencing is a biotechnology to sequence one layer of genomic information for individual cells in a tissue sample. For example, single-cell DNA sequencing is to sequence the DNA from every single cell. Increasing in complexity, single-cell multi-omics sequencing, or single-cell multimodal omics sequencing, is to profile in parallel multiple layers of omics information from a single cell. In practice, single-cell multi-omics sequencing actually detects multiple traits such as DNA, RNA, methylation information and/or protein profiles from the same cell for many individuals in a tissue sample. Multi-omics sequencing has been widely applied to systematically unravel interplay mechanisms of key components and pathways in cell. This survey overviews recent developments in single-cell multi-omics sequencing, and their applications to understand complex diseases in particular the COVID-19 pandemic. We also summarize machine learning and bioinformatics techniques used in the analysis of the intercorrelated multilayer heterogeneous data. We observed that variational inference and graph-based learning are popular approaches, and Seurat V3 is a commonly used tool to transfer the missing variables and labels. We also discussed two intensively studied issues relating to data consistency and diversity and commented on currently cared issues surrounding the error correction of data pairs and data imputation methods. The survey is concluded with some open questions and opportunities for this extraordinary field.

Introducing a Platform for Integrating and Sharing Stem Cell Research Data.

Advancements in regenerative medicine have highlighted the need for increased standardization and sharing of stem cell products to help drive these innovative interventions toward public availability and to increase collaboration in the scientific community. Although numerous attempts and numerous databases have been made to store this data, there is still a lack of a platform that incorporates heterogeneous stem cell information into a harmonized project-based framework. The aim of the platform described in this study, ReMeDy, is to provide an intelligent informatics solution which integrates diverse stem cell product characteristics with study subject and omics information. In the resulting platform, heterogeneous data is validated using predefined ontologies and stored in a relational database. In this initial feasibility study, testing of the ReMeDy functionality was performed using published, publically-available induced pluripotent stem cell projects conducted in in vitro, preclinical and intervention evaluations. It demonstrated the robustness of ReMeDy for storing diverse iPSC data, by seamlessly harmonizing diverse common data elements, and the potential utility of this platform for driving knowledge generation from the aggregation of this shared data. Next steps include increasing the number of curated projects by developing a crowdsourcing framework for data upload and an automated pipeline for metadata abstraction. The database is publically accessible at https://remedy.mssm.edu/.

Pushing the Proteomics Envelope: More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use

Pushing the Proteomics Envelope: More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use

ODFM, an omics data resource from microorganisms associated with fermented foods

ODFM is a data management system that integrates comprehensive omics information for microorganisms associated with various fermented foods, additive ingredients, and seasonings (e.g. kimchi, Korean fermented vegetables, fermented seafood, solar salt, soybean paste, vinegar, beer, cheese, sake, and yogurt). The ODFM archives genome, metagenome, metataxonome, and (meta)transcriptome sequences of fermented food-associated bacteria, archaea, eukaryotic microorganisms, and viruses; 131 bacterial, 38 archaeal, and 28 eukaryotic genomes are now available to users. The ODFM provides both the Basic Local Alignment Search Tool search-based local alignment function as well as average nucleotide identity-based genetic relatedness measurement, enabling gene diversity and taxonomic analyses of an input query against the database. Genome sequences and annotation results of microorganisms are directly downloadable, and the microbial strains registered in the archive library will be available from our culture collection of fermented food-associated microorganisms. The ODFM is a comprehensive database that covers the genomes of an entire microbiome within a specific food ecosystem, providing basic information to evaluate microbial isolates as candidate fermentation starters for fermented food production.